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Simple Summary: Tumor infiltrating lymphocytes (TILs) have been demonstrated as prognostic 
biomarkers in multiple cancer types. Among the various TIL phenotypic sub-populations, T-cells 
are most abundant. Several studies have investigated the prognostic value of CD4+ and CD8+ T-cell 
TILs in head and neck squamous cell carcinoma (HNSCC). In this study we performed a systematic 
review and meta-analysis of available evidence for CD4+ and CD8+ TIL biomarkers in HNSCC. The 
primary aim was to investigate the correlation of TIL sub-population levels and overall survival in 
HNSCC anatomical sub-sites. We demonstrate for the first time that tumor location has a significant 
impact upon the prognostic utility of CD4+ and CD8+ TILs in HNSCC. Such data is of critical im-
portance when incorporating TIL biomarkers into current prognostic models and clinical practice.  
Abstract: Objective: It has been suggested that the presence of tumor-infiltrating lymphocytes (TILs) 
in the tumor microenvironment is associated with a better prognosis in different types of cancer. In 
this systematic review and meta-analysis, we investigated the prognostic role of CD4+ and CD8+ 
TILs in head and neck squamous cell carcinoma (HNSCC). Methods: PubMed, Cochrane, Embase, 
Scopus, and Web of Science were searched up to September 2020. This study was conducted fol-
lowing the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. 
Risk ratios from individual studies were displayed in forest plots and the pooled hazard ratios (HR) 
of death and corresponding confidence intervals (CI) were calculated according to random-effects 
models. Risk of bias of the included studies was assessed through the Newcastle–Ottawa scale. Re-
sults: 28 studies met the inclusion criteria. Studies conducted on HNSCC subsites combined re-
ported a significant reduction in the risk of death for both high CD4+ (HR: 0.77; 95% CI: 0.65-0.93) 
and high CD8+ TILs (HR: 0.64; 95% CI: 0.47–0.88). High CD4+ TILs were associated with signifi-
cantly better overall survival among oropharyngeal HNSCC (HR: 0.52; 95% CI: 0.31–0.89), as well 
as high CD8+ TILS in Human papillomavirus -ve and +ve cancers (HR: 0.39; 95% CI: 0.16–0.93 and 
HR: 0.40; 95% CI 0.21–0.76 respectively). CD8+ TILs were also associated with improved survival in 
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hypopharyngeal cancers (HR = 0.43 CI: 0.30–0.63). No significant association emerged for patients 
with cancer of the oral cavity or larynx. Conclusions: The findings from this meta-analysis demon-
strate the prognostic significance of CD8+ and CD4+ TILs in HNSCC and variation in tumor subsite 
warrants further focused investigation. We highlight how TILs may serve as predictive biomarkers 
to risk stratify patients into treatment groups, with applications in immune-checkpoint inhibitors 
notable areas for further research. 
Keywords: head and neck cancer; tumor-infiltrating lymphocyte; prognosis; TIL; cancer 
 
1. Introduction 
The survival rate for head and neck squamous cell carcinoma (HNSCC) is poor and 
depends on the subsite: in Europe, 5-year survival rates were 45% for oral cavity, 39% for 
the oropharynx, 25% for the hypopharynx, 59% for the larynx [1]. Considering the poor 
survival rates, improved risk stratification is needed to identify patients at higher risk of 
recurrence and to tailor treatment in these patients. Cancer biomarkers, either tissue or 
liquid biopsy-based, are promising tools for detection, assessment of prognosis, and pre-
diction of response to therapy. 
HNSCC is associated with pronounced immunosuppressive tumor activity. In addi-
tion, immunodeficiency has also been shown to correlate with a poor prognosis [2]. Im-
munosuppression creates a favorable environment for HNSCC cells to avoid tumor erad-
ication through immunosurveillance [3,4]. The tumor immune microenvironment (TIM) 
is the immune infiltrate that emerges during tumor growth and several reports have 
shown it has a major role in cancer progression [5]. The TIM includes various tumor-infil-
trating lymphocytes (TILs), which influence cancer invasion and metastasis. TILs have 
been indicated as a promising prognostic marker in multiple cancer types, demonstrating 
comparable or even greater prognostic value than conventional TNM staging [6]. Moreo-
ver, TILs are considered to be a potential predictive biomarker of targeted and immuno-
therapy treatment. Current guidelines recommend the scoring of TILs on histopathologi-
cal specimens (both intra-tumoral and stromal TILs) on a percentage scale [7] and in turn 
tumors are graded as with low, moderate, or high TILs. However, difficulty arises when 
defining clinically relevant cut-off values for ‘high’ TILs tumors, particularly in HNSCC 
where tumor subsite and Human papillomavirus (HPV) status has been shown to have a 
significant impact [8]. For example, across all HNSCC a TIL score of 70% has been shown 
as prognostically significant [9]. However, studies of tumor subsites such as the oral cavity 
or oropharynx report significance with TIL scores as low as 20% [8,10]. 
It has been recently reported that the phenotypic composition of the lymphocytic in-
filtrate may hold additional value and insight when using TILs as cancer biomarkers. In 
solid tumors, T lymphocytes are observed to be the principal component of the TIL com-
partment [11], of which CD4+ T helper cells and CD8+ cytotoxic T cells play pivotal roles. 
Research demonstrates that CD4+ T cells, CD8+ T cells, natural killer (NK) cells, M1 phe-
notype macrophages and dendritic cells (DCs) all have anti-tumoral effects. A coordinated 
and balanced interaction of these subsets is required to guard the host against a develop-
ing tumor [12]. In particular, CD8+ infiltration has been reported to be associated with a 
favorable prognosis in several malignancies [13]. Recent studies have characterized im-
mune infiltrates in the tumor microenvironment of HNSCC and broadly agree that high 
levels of tumor immune cell infiltrates correlate with an improved prognosis. However, 
HNSCC demonstrates significant TIL heterogeneity, further compounded by subsite var-
iation [14]. Direct correlations to survival outcomes have varied with reports disagreeing 
as to the clinical importance of CD4+ compared to CD8+ T cells [15,16]. 
Considering the need for robust biomarkers in HNSCC and the contrasting evidence 
concerning TILs in this cancer group, the aim of this paper was to systematically review 
and perform a meta-analysis of recent evidence concerning the prognostic significance of 
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CD4+ and CD8+ TIL populations in HNSCC. Unlike previous reports, our aim was to pro-
vide particular focus on how tumor subsite and HPV status impacts the utility of a CD4+ 
CD8+ TIL biomarker in HNSCC. 
2. Methods 
2.1. Outcome Measures 
The primary outcome of this meta-analysis is defined as the prognostic role of CD4+ 
and CD8+ cell TIL populations in overall survival (OS, defined as the time from diagnosis 
or initiation of treatment to patient death, irrespective of cause) in HNSCC patients. A 
secondary outcome is the impact of tumor subsite (oral cavity, oropharynx, hypopharynx, 
larynx) and HPV status (as detected by p16 immunohistochemistry, HPV-DNA in situ 
hybridization or PCR) on the above clinical outcome variable. After an initial scoping re-
view of potential studies, we decided we were unable to include additional disease-spe-
cific survival outcome measures, such as disease-free or progression-free survival, due to 
significant heterogeneity and underreporting of these outcomes in studies. 
2.2. Search Strategy 
This systematic review and meta-analysis were conducted following the preferred 
reporting items for systematic reviews and meta-analyses (PRISMA) checklist [17]. Med-
line (via Ovid), Cochrane, Embase (via Ovid), Web of Science (Core Collection) and Sco-
pus were searched from inception through to September 2020. The following keyword 
search was conducted: 
“Head and Neck Neoplasms” OR “Facial Neoplasm” OR “Mouth Neoplasm” OR 
“Otorhinolaryngologic Neoplasm” OR “Tracheal Neoplasm” OR “head and neck neo-
plasm” OR “Carcinoma” OR “Squamous Cell” OR “oral cavity neoplasm” OR “Oropha-
ryngeal Neoplasms” OR “Hypopharyngeal Neoplasms” OR “Laryngeal Neoplasms” OR 
”squamous cell carcinoma” AND “lymphocytes” OR “tumor-infiltrating” OR “tumor-in-
filtrating lymphocytes” OR “lymphocyte, tumor-infiltrating” OR “tumor-infiltrating lym-
phocytes” OR “tumor-infiltrating lymphocyte” OR “tumor-derived activated cells” OR 
“activated cell, tumor-derived” OR “activated cells, tumor-derived” OR “tumor-derived 
activated cells” OR “tumor-derived activated cell” AND “prognosis” OR “risk” OR “re-
currence” OR “mortality” OR “survival” OR “predict” OR “outcome” OR “significant” 
OR “impact” OR “detect” OR “relevant”. 
The reference lists of articles included in this review as well as narrative reviews pub-
lished in the last 10 years were also manually searched to minimize the risk of missing 
data. Two authors (DB and MiT) independently screened all titles and abstracts generated 
by the search and then evaluated the full texts of all the relevant articles identified against 
the inclusion criteria (Figure 1); a third author (MaT) settled discordances when present. 
Any disagreement between the assessors on the suitability of articles for inclusion tackled 
by thorough discussion between assessors, or failing this, by referral to the senior author 
(PBR).  
2.3. Selection Criteria 
Studies were included in the analysis if they met the following criteria: (1) the study 
reports the prognostic role of TILs in squamous cell carcinoma of the head and neck region 
or, specifically, in the oral cavity/oropharynx/larynx/hypopharynx treated with surgery 
and/or chemoradiation therapy with curative intent; (2) the study uses immunohisto-
chemistry (IHC) to categorize specific subsets of TILs in tumor surgical specimens; (3) the 
study reports the association of TIL infiltration and patient survival with sufficient sur-
vival data to extract hazard ratios (HRs) and 95% confidence intervals CI; (4) the analyzed 
tissue had not been previously exposed to radiotherapy and/or chemotherapy (5) the 
study reports specific data for CD8+ TILs in HPV+ and HPV- oropharyngeal SCC. Non-
English studies were excluded. Studies containing aggregated data or duplicated data 
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from previously published work were excluded, as were review articles, case reports, ed-
itorials, and letters. 
2.4. Data Extraction and Statistical Analysis 
The standard error of the log HR was derived from the log CIs. The pooled HR and 
corresponding 95% confidence interval (CI) were calculated according to random-effects 
models of DerSimonian and Laird [18], which incorporates both within-and between-
study variability, as a weighted average of the estimated HRs, by giving each study a 
weight proportional to its precision. Statistical heterogeneity among studies was evalu-
ated using the I² and τ2 statistics [18]. Influence analysis was performed when pooled HR 
were estimated from five or more studies: pooled HR was calculated by omitting one 
study at a time. Publication bias was assessed through a funnel plot [19]. Two authors 
(DB, MiT) independently assessed the quality of the included studies with the Newcastle–
Ottawa Scale [20]. 
The results of the meta-analysis were presented graphically using forest plots, plot-
ting the individual paper and pooled HR and 95% CI. 95% CIs were derived from esti-
mated study variances. Statistical significance was defined as p < 0.05 (two sided). 
3. Results 
Details on the literature search process are shown in the flow chart of Figure 1. 
Twenty-eight studies met the eligibility criteria out of the 3440 initially screened citations 
(Table 1) [15,16,21–46]. Upon contacting the corresponding authors of the papers by Ngu-
yen et al. and Spector et al. it was discovered that there was overlap in patient cohort 
datasets in certain TIL sub-group analyses presented in these studies. Therefore, to allow 
the inclusion of valid data we excluded the replicated data from the later published paper 
of Spector et al., and only included overall HNSCC data from the larger cohort presented 
by Nguyen et al. 
The quality of included studies was high (Newcastle-Ottawa Scale score ≥7) in 21 
(75%) of 28 studies, with a median of 8 (interquartile range 7–8). A detailed report on the 
quality of included studies according to the Newcastle-Ottawa Scale is reported in Sup-
plementary results Table S1. 
3.1. CD4+ and Overall Survival 
Eleven studies reported the association between CD4+ and overall survival (Figure 
2). Three studies reported results for head and neck cancers without information on spe-
cific anatomical subsite; among them, the pooled HR was 0.77 (95% CI: 0.65–0.93), sug-
gesting an inverse association between CD4+ and mortality (Figure 2a). However, this 
association appeared to vary according to specific subsite (Figure 2b–d). CD4+ was asso-
ciated with a lower risk of death for cancer of the oropharynx (pooled HR = 0.52; 95% CI: 
0.31–0.89), but not of the oral cavity (pooled HR = 0.98; 95% CI: 0.96–1.00) and hypophar-
ynx (pooled HR = 0.77; 95% CI: 0.49–1.20). No specific data was available for laryngeal 
cancer. 
3.2. CD8+ and Overall Survival 
Twenty-five studies investigated the association between CD8+ and overall survival 
(Table 1). Among studies that reported results for all head and neck cancer subsites com-
bined (Figure 3), CD8+ was associated with increased survival (pooled HR = 0.64; 95% CI: 
0.47–0.88). No publication bias emerged by funnel plot inspection; further, influence anal-
ysis reported pooled HR ranging from 0.57 (CI: 0.37–0.89) by excluding the study by Ngu-
yen et al. [32] to 0.73 (CI: 0.57–0.94) by excluding the study by Balermpas et al. [15]. 
However, the magnitude of this association may depend upon the proportion of the 
specific intra-tumoral subsite data included in each study, since the prognostic relevance 
of CD8+ in head and neck cancers was found to vary according to intra-tumoral location. 
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CD8+ in oral cancer trended towards improved survival (pooled HR 0.74, 95% CI: 0.54–
1.01) although not to a statistically significant level. Results for intra-tumoral subsite and 
CD8+ in oral cavity cancers appeared largely heterogenous (Figure 4)—tumor core and 
parenchymal CD8+ trended towards an improved survival—while stromal CD8+ was in-
conclusive. Conversely, CD8+ was strongly associated with increased survival in oropha-
ryngeal cancer (Figure 5), in both HPV-negative (pooled HR = 0.39; 95% CI:0.16–0.93) and 
HPV-positive cancers (pooled HR = 0.40; 95% CI:0.21–0.76 on tumor samples and pooled 
HR = 0.34; 95% CI:0.15–0.77 on stromal samples) with HPV status being determined by 
both p16 and DNA in all studies with exception of study by Solomon et al. [37] which 
defined HPV positivity based on p16 immunostaining alone. No publication bias emerged 
by funnel plot inspection for HPV-positive tumor samples. Furthermore, consistent re-
sults emerged from influence analysis, with pooled HR ranging from 0.32 (0.21–0.49) by 
excluding Oguejiofor et al. [33] to 0.47 (0.24–0.91) by excluding Nodfors et al. [16]. Three 
studies reported results for CD8+ and survival in hypopharyngeal cancer (Figure 3d) 
showing increased survival with pooled HR = 0.43 (0.30–0.63). In addition, 3 studies re-
ported results for laryngeal cancer (Figure 3e), showing homogeneous associations with 
increased survival, although not to a significant level (pooled HR = 0.77; 95% CI: 0.57–
1.03). 
 
Figure 1. PRISMA Flow chart of study inclusion process. 
  
PubMed Medline 
(n = 584) 
IDENTIFICATION Embase 
(n = 160) 
SCREENING Titles and abstracts of the papers screened  
(n = 3440) 
ELIGIBILITY Full text articles assessed for eligibility  
(n = 70) 
INCLUDED 
Excluded (n = 3370) 
Reasons: 
- Other topics  
- Duplicated studies 
- Non-English 
- Reviews 
- Case reports 
- Editorials 
Excluded (n = 42) 
Reasons: 
- No extractable data   
- Previous RT or CTRT 
- Case series included in 
previous publications 
- Secondary data 
Full text articles eligible (n = 28) 
Web of Science 




(n = 57) 
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Sample Size Subsite TILs Newcastle–Ottawa Scale 
Chatzopoulos, 2020[23] Greece 1985–2008 283 Larynx CD8 8 
Hu 2020[27] China 2014–2017 111 Hypopharynx CD4, CD8 8 
Landin 2020[29] Sweden 2002–2013 149 Hypopharynx CD8 8 
Boxberg, 2019[46] Germany 2008–2012 66 Oral cavity CD8 6 
Ngamphaiboon, 2019[31] Thailand 2007–2013 203 Head & neck CD8 8 
Shimizu, 2019[36] Japan 2004–2014 139 Oral cavity CD8 8 
Spector, 2019[38] U.S. A. 2008–2014 234 
Head & neck, oral cavity, 
larynx 
CD8 8 
Takahashi, 2019[39] Japan 2000–2012 77 Oral cavity CD4, CD8 5 
Zhou, 2019[43] China 2004–2015 164 Oral cavity, larynx CD8 7 
Ono, 2018[35] Japan 2000–2014 96 Hypopharynx CD4 8 
Solomon, 2018[37] Australia 2002–2012 190 Oropharynx HPV+ CD8 8 
Welters, 2018[41] The Netherlands 2007–2015 97 Oropharynx HPV+ CD4, CD8 6 
Ahn, 2017[21] South Korea 2003–2011 68 Oral cavity CD4, CD8 8 
DeMeulenaere, 2017[24] Belgium 2004–2013 14 Oropharynx HPV+ CD8 8 
Fang, 2017[25] China 2007–2009 78 Oral cavity CD4, CD8 8 
Kogashiwa, 2017[44] Japan 2007–2014 84 Oral cavity CD8 8 
Oguejofor, 2017[33] U. K. 2002–2011 124 Oropharynx HPV-/+ CD8 8 
Wu, 2017[42] China 2008–2015 165 Oral cavity CD8 8 
Kim, 2016[28] South Korea 2005–2012 402 Head & neck CD8 8 
Nguyen, 2016[32] U. S. A. 2008–2012 270 Head & neck, oral cavity CD4, CD8 7 
van Kempen, 2016[40] The Netherlands 1997–2011 262 Oropharynx HPV–/+ CD4, CD8 8 
Balermpas, 2015[15] Germany 2004–2012 161 Head & neck CD8 8 
Oguejofor, 2015[34] U. K. 2002–2011 139 Oropharynx HPV- CD4 7 
Balermpas, 2013[15] Germany 2007–2010 101 Head & neck CD4, CD8 6 
Hasmin, 2013[26] France 2004–2011 83 Head & neck CD8 8 
Nodfors, 2013[16] Sweden 2000–2007 340 Oropharynx HPV-/+ CD8 8 
Maleki, 2011[30] U. S. A. --- 40 Oral cavity CD8 5 
Badoual, 2006[22] France --- 84 Head & neck CD4 7 
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Figure 2. Forest plots for the association between CD4+ tumor-infiltrating lymphocytes and overall survival in head and 
neck cancers, according to subsite (a–d). For each study, hazard ratio (HR) and corresponding 95% confidence interval 
(CI) are reported; HRs are represented through squares, the area is inversely proportional to standard error; 95% CI are 
represented through horizontal lines. Pooled HRs are represented through diamonds.  
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Figure 3. Forest plots for the association between CD8+ tumor-infiltrating lymphocytes and overall survival in head and 
neck cancers, according to subsite (a–e). For each study, hazard ratio (HR) and corresponding 95% confidence interval (CI) 
are reported; HRs are represented through squares, the area is inversely proportional to standard error; 95% CI are repre-
sented through horizontal lines. Pooled HRs are represented through diamonds.  
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Figure 4. Forest plots for the association between CD8+ tumor-infiltrating lymphocytes and overall survival in oral cancer 
according to tumor compartment (a–c). For each study, hazard ratio (HR) and corresponding 95% confidence interval (CI) 
are reported; HRs are represented through squares, the area is inversely proportional to standard error; 95% CI are repre-
sented through horizontal lines. Pooled HRs are represented through diamonds.  
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Figure 5. Forest plots for the association between CD8+ tumor-infiltrating lymphocytes and overall survival in oropha-
ryngeal cancer according to HPV status and tumor compartment (a–c). For each study, hazard ratio (HR) and correspond-
ing 95% confidence interval (CI) are reported; HRs are represented through squares, the area is inversely proportional to 
standard error; 95% CI are represented through horizontal lines. Pooled HRs are represented through diamonds.  
4. Discussion 
4.1. Summary of Results 
The present meta-analysis focused on the prognostic role of elevated CD4+ and CD8+ 
TIL populations in HNSCC, reporting on 28 studies. Our principal finding is that while 
CD4+ and CD8+ TIL populations associate with improved OS in HNSCC, there was con-
siderable heterogeneity in outcomes between different tumor anatomical subsites – pre-
viously unreported in the literature. We observed that across datasets of pooled HNSCC 
anatomical subsites, both CD4+ and CD8+ were associated with improved OS. High CD4+ 
and CD8+ TILs were significantly associated with improved OS among oropharyngeal 
cancers and high CD8+ was associated with improved OS in hypopharyngeal cancers. 
HPV status did not differentiate TIL significance in oropharyngeal cancers. In contrast, 
neither high CD4+ nor CD8+ TILs were associated with improved OS for oral cavity, lar-
yngeal or hypopharyngeal cancers. Trends observed with intra-tumoral CD8+ TIL heter-
ogeneity were inconclusive due to limited studies and anatomical subsite datasets. 
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4.2. Clinical Significance 
Several studies have reported the presence of TILs as a favorable prognostic factor 
for treatment outcomes in different types of cancer [47]. However, different subsets of 
lymphocytes have different functions within the TIM [14] and have been found to infer 
differing prognostic significance. A general observation of our data was that patterns of 
HR significance were maintained among both CD4+ and CD8+ TIL populations for ana-
tomical subsites, indicating that tumor location is a greater discriminating factor than T-
cell subset in HNSCC. 
We are unable to draw any firm conclusions relating to intra-tumoral CD4+/CD8+ 
TIL location and prognostic significance (Figures 4 and 5). In part due to low numbers of 
studies, but also heterogeneity between datasets, study criteria, and number of defined 
intra-tumoral locations. Reports from other cancers, for example colorectal cancer, have 
highlighted prognostic significance of TIL subsets and intra-tumoral heterogeneity [48]. 
Nonetheless, such trends should warrant further investigation and the clinical translation 
of T-cell TIL markers in HNSCC will be dependent upon standardization of such param-
eters. In particular, as HNSCC exhibits high levels of intra-tumoral heterogeneity, of both 
the genomic and immune landscape [49]. 
The HPV status of oropharyngeal cancers is one of very few predictive markers in 
HNSCC [50]. The recent separation of HPV +ve and -ve disease into two different disease 
entities in the 8th Edition of the AJCC staging criteria poses several questions. Notably, 
how can TILs be incorporated into these different prognostic models. In addition, using 
p16 immunostaining as a stand-alone test to define an oropharyngeal carcinoma as HPV-
driven also raises concerns [51]. p16 immunostaining has indeed shown suboptimal sen-
sitivity and insufficient specificity with 10 to 20% of p16-positive oropharyngeal carci-
noma resulting HPV-DNA/RNA negative. Thus, prognostic stratification based on p16 
alone has been found inadequate with respect to one based on more precise biomarkers 
of transforming HPV infections.[52]. The underlying driver of carcinogenesis also appears 
to influence the density and composition of the lymphatic infiltrate - as demonstrated in 
hormone receptor-negative breast cancers which are observed to have higher TIL density 
than hormone receptor-positive breast cancers [53,54]. Given the differing underlying eti-
ology and carcinogenic pathways in HPV+ve and -ve cancers and the role of the TIM in 
invasion and metastasis [55], we had expected to see differing TIL significance in these 
sub-groups. While only CD8+ datasets were available, the prognostic significance re-
mained within both sub-groups. It remains to be seen what prognostic/predictive value 
other TIL phenotypic subsets may hold in the HPV+ve tumor sub-group. 
4.3. Future Work 
To incorporate TIL biomarkers, and specifically T-cell subset markers, into clinical 
practice it is crucial to establish standardized assessment protocols and general cut-off 
values. As previously highlighted, consensus is forming with regard how to assess TILs 
as a whole; however, evidence for phenotypic subset quantification is lacking in HNSCC. 
For the clinical translation of these biomarkers, such standardized protocols are the first 
step to design robust randomized clinical trials to enable more accurate patient treatment 
stratification. Results in other cancer types that indicate an equivalent if not improved 
prognostic value of TILs as biomarkers when compared to conventional TNM classifica-
tion systems are certainly promising for the incorporation of TILs into existing HNSCC 
prognostic models [56,57]. 
To gain a deeper understanding of the TIM, further characterization is needed, in-
cluding identification of phenotypically distinct immune cell populations and their state 
of activation or exhaustion. Novel development of multi-parameter assessment methods 
to view several cell types and corresponding marker expression may facilitate these goals. 
Such as multiplex fluorescence immunohistochemistry, which is a promising technique 
that has the ability to simultaneously assess multiple cell subsets in situ, maximize data 
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harvesting per tissue section, improve the quality and detail of pathological analysis and 
thus efficient tissue use [58]. Finally, at present it is unclear whether conventional treat-
ment protocols for HNSCC inhibit or promote tumor immune response mechanisms. Dis-
tel and Buttner [59] investigated intra-tumoral immune profiles before and after primary 
chemoradiation and concluded that post-therapy cytotoxic T lymphocytes were depleted 
to a lesser extent than immunosuppressive T regulatory cells. Such findings will influence 
the timing of TIL assessment in conventional treatment pathways and the clinical efficacy 
of such values should pre-defined cut-offs be universally endorsed. 
The primary recommendation from this meta-analysis is the need for further studies 
that investigate homogenous patient and/or treatment groups, for example immune-
checkpoint inhibitors, with clearly defined research questions. Key areas of interest will 
be immune cell intra-tumoral heterogeneity and the relationship of therapeutic target 
marker expression, such as programmed death-ligand 1, to TILs and in particular CD4+ 
and CD8+ T-cell subsets. Immunotherapy in HNSCC is poorly served by predictive bi-
omarkers, thus the addition of TIL scores to more accurately stratify these patients may 
hold particular promise. 
4.4. Limitations 
This study has some limitations. Although the number of papers included in this 
study are adequate, some studies did not provide detailed information regarding the sub-
types of TILs or each tumor subsite. In addition, specific treatment groups within studies 
were heterogenous or poorly reported and thus not amendable to individual analysis. The 
prognostic value of TIL biomarkers is likely to differ between different tumor subsites, 
tumor stage, and treatment groups. Due to different cut-off values of the high-density and 
low-density groups of TILs, techniques of detecting TILs, and the source of specimen, the 
level of interstudy heterogeneity was relatively high. 
5. Conclusions 
We have demonstrated that high-density CD4+ and CD8+ TILs were associated with 
improved OS rates in HNSCC. Moreover, tumor location and intra-tumoral subsite sig-
nificantly influenced the prognostic value of these TIL biomarkers – with a clear separa-
tion between oral cavity and oropharyngeal cancers. Our data clearly demonstrates the 
requirement for well-designed prospective studies with the aim of generating standard-
ized TIL assessment protocols for clinical translation. 
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